Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

ReViral (Group)

ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development. The company has developed a novel antiviral programme targeting RSV fusion with highly potent, orally bioavailable inhibitors, strong drug-like characteristics and good pharmacokinetic properties offering versatility in the route of administration. The lead candidate, sisunatovir, completed a Phase 2a trial in adult volunteers, showing high potency and was well tolerated. The company also has an RSV replication programme at an earlier stage of development and plans to expand its pipeline. In July 2018, ReViral completed a $55 million Series B funding round from a group of leading venture capital investors jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors. Existing investors Andera Partners, OrbiMed and Brace Pharma Capital also participated in the fundraising. *

 

Period Start 2011-01-01 established
Products Industry virostatic agent
  Industry 2 RV521 (ReViral Ltd.)
Persons Person Littler, Edward (Eddy) (ReViral 201906– COO before since 201610– CEO before Domainex + Medivir)
  Person 2 Wisniewski, Raphaël (LCF Rothschild 200511 Edmond de Rothschild Investment Partners)
     
Region Region Stevenage, Hertfordshire
  Country United Kingdom (GB)
  Street Gunnels Wood Road
Stevenage Bioscience Catalyst
  City SG1 2FX Stevenage, Hertfordshire
    Address record changed: 2019-10-23
     
Basic data Employees n. a.
     
    * Document for �About Section�: ReViral Ltd.. (10/21/19). "Press Release: ReViral Announces Appointment of Alan Musso as Chief Financial Officer". London.
     
   
Record changed: 2019-10-23

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for ReViral (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top